3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Vascular Diseases
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Cardiovascular Diseases
1
Blood Protein Disorders
1
Interventions
Rituximab
9
Cyclophosphamide
8
fludarabine
5
dacetuzumab
5
blinatumomab
5
Brentuximab Vedotin
4
Bendamustine Hydrochloride
4
ibrutinib
3
fludarabine phosphate
3
Vincristine
3
Prednisone
3
Melphalan
3
Etoposide
3
Doxorubicin
3
tetulomab tetraxetan lu-177
2
ponatinib
2
cobomarsen
2
acalabrutinib
2
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Lutetium
2
Ifosfamide
2
Everolimus
2
Carboplatin
2
Busulfan
2
Bone Marrow Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphatic Diseases
×
ficlatuzumab
×
Lymphoid
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled